180 Life Sciences Corp Stock

$10.24

206.59% yesterday

Nasdaq, Aug 12, 10:19 pm CET

ISIN

US68236V1044

Symbol

ATNF

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

180 Life Sciences Corp Stock price

$10.24

-4,118.46 99.75% 5Y

Nasdaq, Closing price Tue, Aug 12 2025

+6.90 206.59%

ISIN

US68236V1044

Symbol

ATNF

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$514.5m

Enterprise Value

$513.7m

Net debt

positive

Cash

$2.2m

Shares outstanding

6.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | 39.4

EV/Sales

- | 39.3

EV/FCF

negative

P/B

95.6

Financial Health

Equity Ratio

72.5%

Return on Equity

-153.3%

ROCE

-149.0%

ROIC

Debt/Equity

0.3

Financials (TTM | estimate)

Revenue

$0.0 | $13.1m

EBITDA

$-8.0m | -

EBIT

$-8.0m | $-10.7m

Net Income

$-17.2m | $-18.5m

Free Cash Flow

$-3.2m

EPS

$-3.0

FCF per Share

$-0.5

Short interest

2.7%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

180 Life Sciences Corp Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a 180 Life Sciences Corp forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a 180 Life Sciences Corp forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from 180 Life Sciences Corp

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.98 4.98	26% 26% -
- Research and Development Expense	1.51 1.51	32% 32% -
EBITDA	-8 -8	55% 55% -
- Depreciation and Amortization	0.01 0.01	90% 90% -
EBIT (Operating Income) EBIT	-8.02 -8.02	55% 55% -
Net Profit	-17 -17	37% 37% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

180 Life Sciences Corp Stock News

Neutral

PRNewsWire

●

about 15 hours ago

180 Life Sciences (ETHZilla) Holds 82,186 ETH

Company Initiates Institutional ETH Accumulation Strategy PALO ALTO, Calif. , Aug. 12, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), dba ETHZilla (the "Company", "180 Life Sciences" or "ETHZilla"), announced today that is has total holdings of 82,186 Ether ("ETH") at an average acquisition price of $3,806.71, which is now valued at approximately $349 million.

Neutral

PRNewsWire

●

one day ago

180 Life Sciences Announces Closing of Private Offering of Approximately $156 Million of Convertible Notes

Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings This milestone follows the announcement of the Company's recently closed $425 million private placement PALO ALTO, Calif. , Aug. 11, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), (the "Company" or "ETHZilla"), today announced that it has sold approximately $156 million aggre...

Neutral

PRNewsWire

●

8 days ago

180 Life Sciences Closes $425 Million Private Placement to Advance its Ethereum Treasury Strategy

Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings Company plans to execute a differentiated yield generation program, with Company built for the Ethereum community, by the Ethereum community PALO ALTO, Calif. , Aug. 4, 2025 /PRNewswire/ -- 180 Life Sciences Corp. (Nasdaq: ATNF), (the "Company" or "ETHZilla"), has closed its previously ann...

More 180 Life Sciences Corp News

Company Profile

180 Life Sciences Corp. develops pharmaceuticals for chronic pain and inflammatory diseases. It operates as a clinical-stage biotechnology company focused on the development of novel drugs that fulfil unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded in 2016 and is headquartered in Menlo Park, CA.

Head office	United States
CEO	Blair Jordan
Employees	4
Founded	2016
Website	180lifesciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now